This technology employs a TAB algorithm that quantitatively assesses both known and putative tumor-associated antigens and integrates this measure with T cell exhaustion signatures. It leverages clinical data from studies in urothelial and head and neck cancers to determine which patients may benefit from immune checkpoint blockade therapy, even when traditional biomarkers such as tumor mutation burden and PD-L1 levels are low. By capturing the dynamic interplay between antigen burden and T cell activity, the algorithm highlights patients who retain an active T cell repertoire despite reduced CD8 T cell exhaustion.